/SOLV
SOLV Stock - Solventum Corporation
Healthcare|Medical - Care FacilitiesNYSE
$81.59+1.13%
+$0.91 (+1.13%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).67
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.5%upside
Target: $88.53
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SOLV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$80.77 – $82.41
TARGET (TP)$88.50
STOP LOSS$75.06
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$88.20
52W Low$60.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.25B | $8.20B | $8.13B | $8.17B | $7.28B |
| Gross Profit | $4.59B | $4.69B | $4.70B | $4.92B | $4.32B |
| Gross Margin | 55.6% | 57.3% | 57.7% | 60.2% | 59.3% |
| Operating Income | $1.04B | $1.69B | $1.69B | $1.88B | $1.43B |
| Net Income | $479.00M | $1.35B | $1.34B | $1.46B | $1.14B |
| Net Margin | 5.8% | 16.4% | 16.5% | 17.9% | 15.6% |
| EPS | $2.77 | $7.79 | $7.79 | $8.47 | $6.60 |
Company Overview
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
21%
Hold / Neutral
10
71%
Sell / Underperform
1
7%
Analyst Consensus🔴 Bearish
3 Bullish11 Neutral/Bearish
Price Targets
$79
Average Target
↓ 3.6% Downside
Now
$54
Low
$79
Average
$103
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | BTIG Research | Upgrade | Buy | $100 |
| October 1st 2025 | UBS | Initiation | Neutral | $77 |
| September 11th 2025 | Jefferies | Initiation | Hold | $80 |
| July 15th 2025 | Morgan Stanley | Upgrade | Overweight | $103 |
| July 1st 2025 | Argus | Upgrade | Buy | $90 |
| June 6th 2025 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| May 19th 2025 | Piper Sandler | Upgrade | Overweight | $87 |
| December 4th 2024 | Mizuho | Initiation | Neutral | $70 |
| October 8th 2024 | Stifel | Initiation | Buy | $82 |
| October 7th 2024 | Piper Sandler | Initiation | Neutral | $71 |
| September 26th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| September 5th 2024 | BTIG Research | Initiation | Neutral | - |
| June 24th 2024 | Argus | Initiation | Hold | - |
| May 30th 2024 | Goldman | Initiation | Sell | $54 |
| May 10th 2024 | BofA Securities | Initiation | Neutral | $70 |
Earnings History & Surprises
SOLVBeat Rate
100%
Last 7 quarters
Avg Surprise
+11.4%
EPS vs Estimate
Beats / Misses
7/0
Last 12 quarters
Latest EPS
$1.50
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
+18.9%
$2.08vs$1.75
Q3 24
+3.3%
$1.56vs$1.51
Q4 24
+18.0%
$1.64vs$1.39
Q1 25
+7.6%
$1.41vs$1.31
Q2 25
+10.7%
$1.34vs$1.21
Q3 25
+16.6%
$1.69vs$1.45
Q4 25
+4.9%
$1.50vs$1.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $1.50 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.43 | $1.50 | +4.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.45 | $1.69 | +16.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $1.21 | $1.34 | +10.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $1.31 | $1.41 | +7.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $1.39 | $1.64 | +18.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $1.51 | $1.56 | +3.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $1.75 | $2.08 | +18.9% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | — | $0.42 | — | — |
Q3 2023 | Sep 30, 2023 | — | $1.65 | — | — |
Q2 2023 | Jun 30, 2023 | — | $1.86 | — | — |
Q1 2023 | Mar 31, 2023 | — | $1.70 | — | — |
Q4 2022 | Dec 31, 2022 | — | $1.78 | — | — |
Q3 2022 | Sep 30, 2022 | — | $1.94 | — | — |
Q2 2022 | Jun 30, 2022 | — | $2.03 | — | — |
Q1 2022 | Mar 31, 2022 | — | $2.03 | — | — |
Latest News
BTIG Upgrades Solventum to Buy, Announces $100 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 11:05 AM
Solventum shares are trading higher after the company announced it has agreed to acquire Acera Surgical for $725 million in cash plus up to $125 million in contingent cash payments. Its board also authorized a $1 billion stock buyback plan.
📈 PositiveBenzinga•Nov 20, 2025, 05:06 PM
Solventum Agrees To Acquire Acera Surgical For $725M In Cash Plus Up To $125M In Contingent Cash Payments Based On Achievement Of Certain Future Milestones
📈 PositiveBenzinga•Nov 20, 2025, 02:05 PM
Solventum Board Authorizes $1B Share Repurchase Program
📈 PositiveBenzinga•Nov 20, 2025, 02:04 PM
UBS Maintains Neutral on Solventum, Raises Price Target to $79
➖ NeutralBenzinga•Nov 10, 2025, 07:49 PM•Also:
Solventum shares are trading higher after the company reported a Q3 earnings beat and raised FY25 guidance.
📈 PositiveBenzinga•Nov 7, 2025, 05:49 PM
Piper Sandler Maintains Overweight on Solventum, Raises Price Target to $98
📈 PositiveBenzinga•Nov 7, 2025, 12:46 PM
Solventum Raises FY2025 Adj EPS Guidance from $5.80-$5.95 to $5.98-$6.08 vs $5.95 Est
📈 PositiveBenzinga•Nov 6, 2025, 09:19 PM
Solventum Q3 Adj. EPS $1.50 Beats $1.43 Estimate, Sales $2.096B Beat $2.051B Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:18 PM
UBS Initiates Coverage On Solventum with Neutral Rating, Announces Price Target of $77
➖ NeutralBenzinga•Oct 1, 2025, 12:20 PM
Wells Fargo Maintains Equal-Weight on Solventum, Raises Price Target to $82
➖ NeutralBenzinga•Sep 15, 2025, 02:11 PM
Jefferies Initiates Coverage On Solventum with Hold Rating, Announces Price Target of $80
➖ NeutralBenzinga•Sep 11, 2025, 11:02 AM
Solventum Upsizes $2B Tender Offer For Outstanding Notes; Pricing Terms Finalized Under Modified August 22 Offer To Purchase
📈 PositiveBenzinga•Sep 8, 2025, 06:34 PM
Frequently Asked Questions about SOLV
What is SOLV's current stock price?
Solventum Corporation (SOLV) is currently trading at $81.59 per share. The stock has moved +1.13% today.
What is the analyst price target for SOLV?
The average analyst price target for SOLV is $88.50, based on 1 analyst.
What sector is Solventum Corporation in?
Solventum Corporation operates in the Healthcare sector, specifically within the Medical - Care Facilities industry. The company is traded on the NYSE exchange.
What is SOLV's market cap?
Solventum Corporation has a market capitalization of $14.15 billion, making it a large-cap company.
Does SOLV pay dividends?
No, Solventum Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGN
Align Technology, Inc.
$157.69
Mkt Cap: $11.3B
DOCS
Doximity, Inc.
$43.65
Mkt Cap: $8.2B
EHC
Encompass Health Corporation
$106.39
Mkt Cap: $10.7B
ELAN
Elanco Animal Health Incorporated
$22.30
Mkt Cap: $11.1B
ENSG
The Ensign Group, Inc.
$181.39
Mkt Cap: $10.4B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
RDY
Dr. Reddy's Laboratories Limited
$14.18
Mkt Cap: $11.8B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
UHS
Universal Health Services, Inc.
$227.46
Mkt Cap: $14.7B
Explore stocks similar to SOLV for comparison